{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:43:25Z","timestamp":1781934205733,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This retrospective study evaluated the outcome and safety of long-term treatment with zoledronic acid, in both polyostotic and mono-ostotic fibrous dysplasia (FD) of children.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The case records of children and adolescents with symptomatic FD who received zoledronic acid (0.1 mg\/kg IV infusion over 1 h) and have completed at least 2 years follow-up were analyzed. The relevant details were recorded in a predesigned chart. Clinical assessment [pain assessment by visual analog scale (VAS) and incidence of new fracture], radiological changes (cortical thickening, ossification, and decrease in the diameter of the osteolytic lesions) and biochemical parameters [alkaline phosphatase (ALP)] were used to evaluate the improvement.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The mean age of presentation was 9.1 years, with four males and six females. All patients had symptomatic FD in the lower limb with complaints of pain, tenderness, swelling, or deformity. Four children had associated pathological fracture. The radiological evaluation with bone scan revealed polyostotic involvement in eight patients and mono-ostotic involvement in two patients. Three patients had associated systemic features like caf\u00e9-au-lait spots or precocious puberty. The fracture united within 3 months and the radiological improvement was evident in the form of filling of the osteolytic defect. The pain score in six patients showed significant improvement (VAS &amp;lt; 3). The ALP level decreased to 544.12 \u00b1 47.35 IU\/L from an initial value of 895.75 \u00b1 79.64 IU\/L (<jats:italic>p<\/jats:italic> = 0.04) at 12 months. One patient had symptomatic hypocalcaemia after zoledronic acid infusion.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The clinical and radiological response of zoledronic acid treatment in FD of children is promising. Further randomized control trials with a larger sample size are required to establish this drug as a first-line medical treatment in FD.<\/jats:p>","DOI":"10.3389\/fped.2020.582316","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T05:05:25Z","timestamp":1606194325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia"],"prefix":"10.3389","volume":"8","author":[{"given":"Sujit Kumar","family":"Tripathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti","family":"Swaroop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Velagada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashree","family":"Priyadarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi Ranjan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanhaiyalal","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"B1","first-page":"389","article-title":"Fibrous dysplasia","volume":"10","author":"Lietman","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"key":"B2","first-page":"29","article-title":"McCune albright syndrome (MCAS): a case series","volume":"40","author":"Rao","year":"2003","journal-title":"Indian Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11914-016-0317-0","article-title":"Fibrous dysplasia\/McCune-albright syndrome: clinical and translational perspectives","volume":"14","author":"Robinson","year":"2016","journal-title":"Curr Osteoporos Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"P120","DOI":"10.1359\/jbmr.06s223","article-title":"G(s) alpha mutations in fibrous dysplasia and McCune-Albright syndrome","volume":"21","author":"Weinstein","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1515\/JPEM.2006.19.S2.583","article-title":"Study group for Gs alpha protein related diseases of the italian society for pediatric endocrinology and diabetes. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome","volume":"19","author":"Lala","year":"2006","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1359\/jbmr.06s222","article-title":"Medical therapy in adults with fibrous dysplasia of bone","volume":"21","author":"Chapurlat","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","article-title":"Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis","volume":"22","author":"Brown","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1515\/JPEM.2009.22.8.763","article-title":"Zoledronate in osteogenesis imperfecta","volume":"22","author":"Panigrahi","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of long-term bisphosphonate therapy in mccune-albright syndrome and polyostotic fibrous dysplasia","volume":"32","author":"Majoor","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4158\/EP10136.CR","article-title":"Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review","volume":"16","author":"Mansoori","year":"2010","journal-title":"Endocr Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00296-014-3132-x","article-title":"Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction","volume":"35","author":"Wu","year":"2015","journal-title":"Rheumatol Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2329483","article-title":"Use of zoledronic acid in paediatric craniofacial fibrous dysplasia","volume":"2016","author":"Di Pede","year":"2016","journal-title":"Case Rep Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/670809","article-title":"Characteristics and treatment results of 5 patients with fibrous dysplasia and review of the literature","volume":"2015","author":"Kutbay","year":"2015","journal-title":"Case Rep Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4158\/EP-2018-0328","article-title":"Efficacy and safety of bisphosphonate therapy in Mc cune-albright syndrome-related polyostotic fibrous dysplasia: a single-center experience","volume":"25","author":"Wang","year":"2019","journal-title":"Endocr Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2002.37421","article-title":"Preclinical pharmacology of zoledronic acid","volume":"29","author":"Green","year":"2002","journal-title":"Semin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2106\/JBJS.D.02942","article-title":"Fibrous dysplasia. Pathophysiology, evaluation, and treatment","volume":"87","author":"DiCaprio","year":"2005","journal-title":"J Bone Joint Surg Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/jbmr.2894","article-title":"Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study","volume":"31","author":"Benhamou","year":"2016","journal-title":"J Bone Miner Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/080352500750028816","article-title":"Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome","volume":"89","author":"Lala","year":"2000","journal-title":"Acta Paediatrica"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J Clin Endocrin Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00223-013-9829-0","article-title":"Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia","volume":"94","author":"Thomsen","year":"2014","journal-title":"Calcif Tissue Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J Bone Miner Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","article-title":"Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases","volume":"25","author":"Ganda","year":"2014","journal-title":"Osteoporos Int."},{"key":"B26","first-page":"504","article-title":"Fibrous dysplasia and McCune-Albright syndrome: an experience from a tertiary care centre in north India","volume":"133","author":"Bhadada","year":"2011","journal-title":"Indian J Med Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00256-017-2698-2","article-title":"Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome","volume":"46","author":"Corsi","year":"2017","journal-title":"Skeletal Radiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bone.2019.01.004","article-title":"Serum periostin levels and severity of fibrous dysplasia of bone","volume":"121","author":"Guerin Lemaire","year":"2019","journal-title":"Bone"},{"key":"B29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1515\/jpem-2015-0300","article-title":"Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome","volume":"29","author":"Tessaris","year":"2016","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"RJ01","DOI":"10.7860\/JCDR\/2017\/24349.9177","article-title":"Zebra stripe sign and bone in bone sign in cyclical bisphosphonate therapy","volume":"11","author":"Chakraborty","year":"2017","journal-title":"J Clin Diagn Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/tp.2017.09.10","article-title":"Zoledronic acid in pediatric metabolic bone disorders","volume":"6","author":"Bowden","year":"2017","journal-title":"Transl Pediatr."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.582316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T05:05:28Z","timestamp":1606194328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.582316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":31,"alternative-id":["10.3389\/fped.2020.582316"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.582316","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"article-number":"582316"}}